New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston


ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that further ocriplasmin clinical and health economic data was presented at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS). The meeting was held from August 11th through August 15th, 2017 in Boston, MA.

The first poster presentation was 'Comparison of Visual Results in Patients Receiving Vitrectomy for Macular Hole in One Eye and Ocriplasmin for Vitreomacular Traction in the Fellow Eye' by Arshad M. Khanani, Greggory Gahn, Victor Gonzalez, Joseph Markoff, Hamzah Khalaf.

Arshad M. Khanani MD, MA, Managing Partner and Director of Clinical Research, Sierra Eye Associates and Clinical Associate Professor, University of Nevada, Reno presented the results from his retrospective analysis designed to determine the difference in best-corrected visual acuity (BCVA) in patients receiving a pars plana vitrectomy (PPV) in the eye with full-thickness macular hole (FTMH) and ocriplasmin for the fellow eye with vitreomacular traction (VMT) but no FTMH.

In his conclusion, Dr Khanani commented:

"Patients who underwent PPV for FTMH benefited from early ocriplasmin treatment in their other eye with VMT that had not progressed to FTMH. Administering ocriplasmin to these patients could potentially avoid development of FTMH in the VMT eye thus avoiding a second PPV."

The second poster presentation, entitled 'Budget Impact Analysis of Ocriplasmin for the Treatment of Vitreomacular Traction in the United States' by Peter Kaiser, Tiffany M. Yu, Pravin U. Dugel, Julia A. Haller, Rohit Varma, Renée JG Arnold presented data from the OASIS randomized trial, a 2-year follow-up study evaluating Ocriplasmin for the treatment of symptomatic VMA (VMT) including macular hole.

Peter K. Kaiser, MD, Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, presented a new budget impact model that was developed in accordance with the principles of good practice published by the International Society for Pharmacoeconomics and Outcomes Research.

Dr Kaiser concluded:

"The use of ocriplasmin injections for VMT may be affordable to US health plans, as its costs could be offset by an expected reduction in the number of PPVs and a reduction in overall complications. Future research on the cost-effectiveness of ocriplasmin in patients with VMT will be forthcoming to further determine the economic impact of ocriplasmin injections."


ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics is currently enrolling patients in a Phase II clinical study evaluating THR- 317, a PIGF inhibitor that is being developed for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments.

ThromboGenics is also conducting a Phase II clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR).

In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was inlicensed from Galapagos, are in late stage pre-clinical development.

ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Novartis commercializes JETREA® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More info available at



Interested in a regular update of the Life Sciences and biotech sector in Flanders?